Antoni Ribas

72PUBLICATIONS
408CO-AUTHORS
Molecular targetsGene and molecular therapyPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Biologically active molecules
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (72)

|Aug 20, 2026
Targeting cancer-intrinsic protein neddylation bypasses the loss of JAK/STAT signaling and overcomes acquired resistance to immunotherapy.

|Aug 12, 2026
COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma.

|Jun 23, 2026
Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy.

|May 12, 2026
Whole-protein screening and multi-modal profiling of antigen-specific CD4+ T cells at single-cell resolution.

|Apr 21, 2026
Cellular Neighborhoods Govern Antitumor T-cell Infiltration Following Anti-CTLA-4 in Melanoma with Primary Resistance to Anti-PD-1.

|Apr 21, 2026
MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition.

Pageof 12

Frequent Collaborators

12 joint publications

Katie M Campbell

9 joint publications

Anusha Kalbasi

9 joint publications

Georgina V Long

8 joint publications

Bartosz Chmielowski